These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 11861393

  • 21. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
    Peng CY, Chen TC, Hung SP, Chen MF, Yeh CT, Tsai SL, Chu CM, Liaw YF.
    Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
    [Abstract] [Full Text] [Related]

  • 22. BRCA1 is differentially expressed in human tumor cells.
    Meng QH, Yuan RQ, Goldberg ID, Rosen EM, Fan SJ.
    Shi Yan Sheng Wu Xue Bao; 2001 Mar; 34(1):55-64. PubMed ID: 12549011
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
    Mizuarai S, Yamanaka K, Kotani H.
    Cancer Res; 2006 Jun 15; 66(12):6319-26. PubMed ID: 16778209
    [Abstract] [Full Text] [Related]

  • 25. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
    Bazan V, Migliavacca M, Tubiolo C, Macaluso M, Zanna I, Corsale S, Amato A, Calò V, Dardanoni G, Morello V, La Farina M, Albanese I, Tomasino RM, Gebbia N, Russo A.
    J Cell Physiol; 2002 May 15; 191(2):237-46. PubMed ID: 12064467
    [Abstract] [Full Text] [Related]

  • 26. Guilt by association? p53 and the development of aneuploidy in cancer.
    Duensing A, Duensing S.
    Biochem Biophys Res Commun; 2005 Jun 10; 331(3):694-700. PubMed ID: 15865924
    [Abstract] [Full Text] [Related]

  • 27. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
    Aghmesheh M, Nesland JM, Kaern J, Dorum A, Edwards L, Byth K, Friedlander M, Jackson P, Tucker KM, Russell PJ.
    Gynecol Oncol; 2004 Dec 10; 95(3):430-6. PubMed ID: 15581943
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Regulation of telomerase and its hTERT messenger in colorectal cancer.
    Boldrini L, Faviana P, Gisfredi S, Donati V, Zucconi Y, Ursino S, Simi P, Baldinotti F, Berti P, Galleri D, Materazzi G, Basolo F, Miccoli P, Pingitore R, Fontanini G.
    Oncol Rep; 2004 Feb 10; 11(2):395-400. PubMed ID: 14719074
    [Abstract] [Full Text] [Related]

  • 30. Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells.
    Tepper CG, Gregg JP, Shi XB, Vinall RL, Baron CA, Ryan PE, Desprez PY, Kung HJ, deVere White RW.
    Prostate; 2005 Dec 01; 65(4):375-89. PubMed ID: 16037992
    [Abstract] [Full Text] [Related]

  • 31. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
    Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, Gudkov AV.
    Cancer Res; 2003 Jun 01; 63(11):2905-12. PubMed ID: 12782597
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis.
    Lin SC, Lee KF, Nikitin AY, Hilsenbeck SG, Cardiff RD, Li A, Kang KW, Frank SA, Lee WH, Lee EY.
    Cancer Res; 2004 May 15; 64(10):3525-32. PubMed ID: 15150107
    [Abstract] [Full Text] [Related]

  • 34. Loss of heterozygosity and p53 expression in Pterygium.
    Reisman D, McFadden JW, Lu G.
    Cancer Lett; 2004 Mar 31; 206(1):77-83. PubMed ID: 15019163
    [Abstract] [Full Text] [Related]

  • 35. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice.
    Bouffler SD, Kemp CJ, Balmain A, Cox R.
    Cancer Res; 1995 Sep 01; 55(17):3883-9. PubMed ID: 7641208
    [Abstract] [Full Text] [Related]

  • 36. P53 is a regulator of the metastasis suppressor gene Nm23-H1.
    Chen SL, Wu YS, Shieh HY, Yen CC, Shen JJ, Lin KH.
    Mol Carcinog; 2003 Apr 01; 36(4):204-14. PubMed ID: 12669312
    [Abstract] [Full Text] [Related]

  • 37. Telomerase deletion limits progression of p53-mutant hepatocellular carcinoma with short telomeres in chronic liver disease.
    Lechel A, Holstege H, Begus Y, Schienke A, Kamino K, Lehmann U, Kubicka S, Schirmacher P, Jonkers J, Rudolph KL.
    Gastroenterology; 2007 Apr 01; 132(4):1465-75. PubMed ID: 17433324
    [Abstract] [Full Text] [Related]

  • 38. Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity.
    Kasiappan R, Shih HJ, Chu KL, Chen WT, Liu HP, Huang SF, Choy CO, Shu CL, Din R, Chu JS, Hsu HL.
    Mol Cancer Res; 2009 Apr 01; 7(4):536-48. PubMed ID: 19372582
    [Abstract] [Full Text] [Related]

  • 39. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis.
    Kiaris H, Chatzistamou I, Trimis G, Frangou-Plemmenou M, Pafiti-Kondi A, Kalofoutis A.
    Cancer Res; 2005 Mar 01; 65(5):1627-30. PubMed ID: 15753354
    [Abstract] [Full Text] [Related]

  • 40. Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53.
    Kichina JV, Rauth S, Das Gupta TK, Gudkov AV.
    Oncogene; 2003 Jul 31; 22(31):4911-7. PubMed ID: 12894234
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.